in vivo mRNA transfection reagent for animal injections
- Adaptable: Suited for any injection route to target any organ
- Safe: Maintain healthy animals and organs
- Time-saving: Ready-to-use reagent with an easy protocol
- Tailored: Customized protocols from in vivo delivery experts
in vivo-jetRNA® transfection reagent
Vaccination / immunization
All organs (depending on the injection route)
Various administration routes (systemic or local)
|Number of injections in mice|
1 mL is sufficient to perform at least 50 intravenous injections or 100 intramuscular injections
5 °C ± 3°C
in vivo transfection reagents are the most powerful alternative to viral vectors for nucleic acid delivery. They are easy to use, cost-effective and considered as safe and efficient vehicles for RNA delivery. mRNA transfection is rapidly emerging as a promising method for nucleic acid-based therapy and offers an attractive substitute to plasmid DNA. Non-viral mRNA delivery methods have already proven their efficiency in vaccination through antigen presenting cells modification and in anti-cancer therapy by directly targeting malignant cells. The intrinsic advantage of mRNA-based immunotherapy relies on the self-adjuvant activity of mRNA and the fact that small amounts of encoded antigen are sufficient to obtain robust immune response.
in vivo-jetRNA® is a transfection reagent specifically developed to deliver mRNA in vivo. This reagent can be used to target multiple organs, by using systemic or local injection routes, in various animal models. mRNA delivery using in vivo-jetRNA® is user-friendly, with a simple 2-step protocol and can be used for vaccination purposes, anti-cancer studies, genome editing using CRISPR/Cas9 method or protein replacement.
|Reference Number||Volume of in vivo-jetRNA®||Volume of mRNA Buffer|
|204-03||0.3 mL||10 mL|
|204-10||1 mL||2 x 10 mL|
Adaptable: target your organ of choice via different administration routes in various animal models, including mice
in vivo-jetRNA® is the reagent of choice to deliver mRNA to various organs using different administration routes (Fig.1). This is attributable to its intrinsic properties: in vivo-jetRNA® protects its payload against ubiquitous endonucleases, prevent non-specific interactions with proteins and promote efficient cell entry.
Choice of the administration route leads to different mRNA biodistribution. in vivo-jetRNA®-mediated mRNA delivery leads to gene expression in numerous organs, through intraperitoneal injection, especially in the spleen and nodes that have a major role in the immune response but also in other organs such as liver, pancreas and uterus (Fig. 2).
Being a non-viral delivery reagent, in vivo-jetRNA® can be safely administered in animals. By avoiding conventional vaccine approaches, it allows to generate a new class of vaccines that rely on direct gene transfer. This concept has several advantages – it is safer for the recipients, faster and cheaper to produce compared to viral vector vaccines or peptide loaded APC (Antigen Presenting Cells), and it has an immense potential to tackle many unmet medical needs.
Fig. 1: Biodistribution of mRNA/in vivo–jetRNA® complexes via different administration routes in mice. Complexes were formed using the recommended conditions with mRNA/in vivo-jetRNA® and were injected via intramuscular, intravenous or intraperitoneal administration routes in mice. Fluorescence signals were observed with Bioluminescence imaging using IVIS system (PerkinElmer) for both Cy7 (on the left) and Luciferase (on the right).
Fig. 2: Distribution of mRNA delivered by in vivo-jetRNA® in mice through intraperitoneal injection. Complexes were formed using the recommended conditions with luciferase mRNA/in vivo-jetRNA® and were injected via intraperitoneal (IP) administration routes in mice. 24 hours after injection, different organs were extracted and luciferase expression was measured.
Safe: mRNA vaccines without any sign of toxicity
in vivo-jetRNA® is the best choice in terms of safety. There are no secondary effects after injection, all animals remain healthy and no animal pain has been encountered. After administration of mRNA – in vivo-jetRNA® complexes by any administration route, targeted organ remains phenotypically intact and no tissue damage is observed.
Time saving with a ready-to-use solution
in vivo-jetRNA® comes with a simple and straightforward protocol. in vivo-jetRNA®/mRNA complex solution is prepared in two steps and ready to be injected to the animal in 15 minutes: a gain of time with minimal effort (Fig. 4).
Fig. 4: in vivo-jetRNA® protocol. This two-step protocol is suitable with direct injection of in vivo-jetRNA®/mRNA complexes through any systemic or local administration route.
Our friendly scientific support team use their scientific expertise to provide protocols tailored to meet your needs.
Immunization or vaccination is a process of introducing novel antigens to the immune system and enabling their recognition, leading to a specific immune response later on. Instead of presenting the whole inactivated pathogens or their partial forms as proteins/peptides to the immune system, mRNA coding for a relevant antigen complexed with in vivo-jetRNA® can be administered to the organism. This mRNA vaccine leads to generation of the appropriate antigen in the organism which elicit the subsequent immune response.
in vivo functional studies
in vivo-jetRNA® is ideal to study gene function in vivo and provides the easiest method for the corroboration of in vitro study. in vivo-jetRNA® is especially suited for gene expression in cells that are usually difficult to transfect, such as slow diving cells or cells that have developed specific mechanisms to protect their genome.
in vivo gene editing using CRISPR/Cas9 system
The latest gene editing tool, CRISPR/Cas9 system, has proven to be an elegant solution for gene therapy. CRISPR/Cas9 in combination with in vivo-jetRNA® provides both precise delivery and effectiveness, giving rise to promising anti-cancer therapeutics.
“We were very happy with the performance of jetMESSENGER and in vivo-jetRNA in delivering our antigen-expressing mRNA to a variety of cells in vitro and in vivo. The response achieved in relation to dose exceeded our expectations, without any observable adverse effect from the formulation.” – Remi C., Columbia University, New York, NY
Each lot of in vivo-jetRNA® is tested in-house with a proprietary test following standard protocol. A sterility test is assessed for each lot. Every batch will be provided with Certificate of Analysis.
Polyplus-transfection® is ISO 9001 Quality Management System accredited since 2002; this level of certification assures global customers that the supplier has established reliable and effective processes for product development, manufacturing, sales and customer support.